

Synthesis of 3-aryl-6a-methyl-6-nitro-1-phenylhexahydrothieno[2,3-d]pyrazole 4,4-dioxides

Valentina M. Berestovitskaya,^{*a} Irina E. Efremova,^a Lidiya V. Lapshina,^a
Anna V. Serebryannikova,^a Vladislav V. Gurzhiy^b and Victoria V. Abzianidze^a

^a A. I. Herzen State Pedagogical University of Russia, 191186 St. Petersburg, Russian Federation.

Fax: +7 812 571 3800; e-mail: kohrgpu@yandex.ru

^b Department of Crystallography, St. Petersburg State University, 199034 St. Petersburg, Russian Federation.

E-mail: vladge017@mail.ru

DOI: 10.1016/j.mencom.2015.05.010


Reaction of 2-benzylidene-3-methyl-4-nitro-3-thiolene 1,1-dioxides and phenylhydrazine affords 3-aryl-6a-methyl-6-nitro-1-phenylhexahydrothieno[2,3-d]pyrazole 4,4-dioxides in moderate yields.

Functionalized thiolene and thiolane 1,1-dioxides are widely used for constructing substances with valuable properties.^{1–4} Condensed polycyclic derivatives of sulfolane can serve as anthracycline antibiotics, inhibitors of influenza virus neuraminidase, and a variety of natural compounds precursors.^{5–7} *s-trans*-Fixed 2-benzylidene-3-methyl-4-nitro-3-thiolene 1,1-dioxides turned to be efficient substrates for creating polynuclear structures.⁸ Their reaction with dihydroresorcinol proceeding as Michael addition–cyclization affords tricyclic structures comprising condensed cycles of hexahydrochromene and sulfolane.⁹

The current work describes the reaction of 2-benzylidene-3-methyl-4-nitro-3-thiolene 1,1-dioxides **1a–d** with phenylhydrazine. This reaction proceeds in ethanol at room temperature and completes within 24 h to give colourless crystal 3-aryl-6a-methyl-6-nitro-1-phenylhexahydrothieno[2,3-d]pyrazole 4,4-dioxides **2a–d**.[†] According to ¹H NMR data they are formed

as mixtures of two diastereomers (~10:1), the major one being isolated by crystallization.

The probable reaction pathway consists of two consequent Michael addition processes (see Scheme 1 and *cf.* ref. 9).



Scheme 1

[†] General procedure for the synthesis of compounds **2a–d**. Freshly distilled phenylhydrazine (0.21 g, 2 mmol) was added to the suspension of 2-benzylidene-3-methyl-4-nitro-3-thiolene 1,1-dioxide **1a–d** (1 mmol) in ethanol (10 ml). The mixture was stirred at room temperature for 24 h. After that the obtained precipitate was filtered off and dried at ambient temperature.

(3*S**,3*aR**,6*aR**,6*S**)-6*a*-Methyl-6-nitro-1,3-diphenylhexahydrothieno[2,3-*d*]pyrazole 4,4-dioxide **2a**. The colourless crystals (0.15 g, 40%) of the diastereomeric mixture (10:1) were obtained. The major diastereomer was isolated by crystallization from propan-2-ol. Yield, 0.13 g (35%), colourless crystals, mp 148–150°C (propan-2-ol). IR (ν/cm^{-1}): 1126, 1320 (SO₂), 1364, 1565 (NO₂), 3262 (NH). ¹H NMR, δ : 1.30 (s, 3H, Me), 3.89 (dd, 1H, C⁵H', ²J_{H'H''} 14.7 Hz, ³J_{H'C⁶H} 6.7 Hz), 3.96 (dd, 1H, C⁵H'', ²J_{H'H''} 14.7 Hz, ³J_{H'C⁶H} 6.1 Hz), 4.54 (d, 1H, C^{3a}H, ³J_{H'C^{3a}H} 4.9 Hz), 5.09 (dd, 1H, C³H, ³J_{H'C^{3a}H} 4.9 Hz, ³J_{H'C³NH} 14.0 Hz), 5.53 (d, 1H, NH, ³J_{H'C³NH} 14.0 Hz), 5.75 (dd, 1H, C⁶H, ³J_{H'C⁶H} 6.7 Hz, ³J_{H'C⁶H} 6.1 Hz), 6.99–7.04 (m, 1H, Ph-N), 7.25–7.29 (m, 4H, Ph-N), 7.32–7.47 (m, 5H, Ph-C). ¹³C NMR, δ : 19.29 (Me), 54.75 (C⁵), 62.30 (C³), 74.81 (C^{3a}), 77.38 (C^{6a}), 89.17 (C⁶), 120.86, 123.07, 126.47, 127.65, 128.51, 128.76, 134.40, 147.21 (Ph, Ar). Found (%): C, 57.83; H, 5.11; N, 11.35. Calc. for C₁₈H₁₉N₃O₄S (%): C, 57.90; H, 5.13; N, 11.25. For the minor diastereomer, ¹H NMR, δ : 1.25 (s, 3H, Me), 4.05–4.20 (m, 2H, C⁵H₂), 5.86–5.88 (m, 1H, C⁶H), signals of other protons virtually coincide with those for the major diastereomer.

3-(4-Chlorophenyl)-6*a*-methyl-6-nitro-1-phenylhexahydrothieno[2,3-*d*]pyrazole 4,4-dioxide **2b**. Yield, 0.11 g (28%), colourless crystals, mp 149–153°C. IR (ν/cm^{-1}): 1119, 1323 (SO₂), 1366, 1556 (NO₂), 3274 (NH). ¹H NMR, δ : 1.29 (s, 3H, Me), 3.89 (dd, 1H, C⁵H', ²J_{H'H''} 14.8 Hz, ³J_{H'C⁶H} 6.7 Hz), 3.95 (dd, 1H, C⁵H'', ²J_{H'H''} 14.8 Hz, ³J_{H'C⁶H} 5.8 Hz), 4.55 (d, 1H, C^{3a}H, ³J_{H'C^{3a}H} 4.9 Hz), 5.12 (dd, 1H, C³H, ³J_{H'C^{3a}H} 4.9 Hz,

³J_{H'C³NH} 14.0 Hz), 5.55 (d, 1H, NH, ³J_{H'C³NH} 14.0 Hz), 5.74 (dd, 1H, C⁶H, ³J_{H'C⁶H} 6.7 Hz, ³J_{H'C⁶H} 5.8 Hz), 6.99–7.03 (m, 1H, Ph), 7.26–7.29 (m, 4H, Ph), 7.41 (d, 2H, C₆H₄, ³J_{HH} 8.9 Hz), 7.45 (d, 2H, C₆H₄, ³J_{HH} 8.9 Hz). ¹³C NMR, δ : 19.28 (Me), 54.71 (C⁵), 61.82 (C³), 74.77 (C^{3a}), 77.49 (C^{6a}), 89.13 (C⁶), 120.86, 123.15, 128.24, 128.48, 128.77, 132.95, 133.33, 147.06 (Ph, Ar). Found (%): C, 53.30; H, 4.41; N, 10.42. Calc. for C₁₈H₁₈ClN₃O₄S (%): C, 53.01; H, 4.45; N 10.30.

3-(4-Bromophenyl)-6*a*-methyl-6-nitro-1-phenylhexahydrothieno[2,3-*d*]pyrazole 4,4-dioxide **2c**. Yield, 0.13 g (31%), colourless crystals, mp 149–151°C (propan-2-ol). IR (ν/cm^{-1}): 1120, 1329 (SO₂), 1364, 1559 (NO₂), 3273 (NH). ¹H NMR, δ : 1.29 (s, 3H, Me), 3.89 (dd, 1H, C⁵H', ²J_{H'H''} 14.7 Hz, ³J_{H'C⁶H} 6.7 Hz), 3.96 (dd, 1H, C⁵H'', ²J_{H'H''} 14.7 Hz, ³J_{H'C⁶H} 6.1 Hz), 4.54 (d, 1H, C^{3a}H, ³J_{H'C^{3a}H} 4.9 Hz), 5.06 (dd, 1H, C³H, ³J_{H'C^{3a}H} 4.9 Hz, ³J_{H'C³NH} 13.7 Hz), 5.53 (d, 1H, NH, ³J_{H'C³NH} 13.7 Hz), 5.75 (dd, 1H, C⁶H, ³J_{H'C⁶H} 6.7 Hz, ³J_{H'C⁶H} 6.1 Hz), 6.99–7.03 (m, 1H, Ph), 7.27–7.29 (m, 4H, Ph), 7.38 (d, 2H, C₆H₄, ³J_{HH} 8.5 Hz), 7.56 (d, 2H, C₆H₄, ³J_{HH} 8.5 Hz). ¹³C NMR, δ : 19.36 (Me), 54.79 (C⁵), 61.94 (C³), 74.79 (C^{3a}), 77.57 (C^{6a}), 89.19 (C⁶), 120.92, 121.07, 123.21, 128.60, 128.83, 131.54, 133.88, 147.12 (Ph, Ar). Found (%): C, 47.63; H, 4.15; N, 9.53. Calc. for C₁₈H₁₈BrN₃O₄S (%): C, 47.80; H, 4.01; N, 9.29.

6*a*-Methyl-6-nitro-1-phenyl-3-*p*-tolylhexahydrothieno[2,3-*d*]pyrazole 4,4-dioxide **2d**. Yield: 0.11 g (38%), colourless crystals, mp 150–154°C (propan-2-ol). IR (ν/cm^{-1}): 1120, 1329 (SO₂), 1364, 1557 (NO₂), 3275 (NH). ¹H NMR, δ : 1.29 (s, 3H, Me), 2.33 (s, 3H, MeAr) 3.87 (dd, 1H, C⁵H', ²J_{H'H''} 14.7 Hz, ³J_{H'C⁶H} 6.7 Hz), 3.94 (dd, 1H, C⁵H'', ²J_{H'H''} 14.7 Hz, ³J_{H'C⁶H} 6.1 Hz), 4.52 (d, 1H, C^{3a}H, ³J_{H'C^{3a}H} 4.9 Hz), 5.08 (dd, 1H, C³H,

The structure of new compounds **2a–d** was confirmed by elemental analysis, IR and NMR (^1H , ^{13}C , HMQC, HMBC) spectroscopy.[‡] IR spectra of these compounds contain vibrational bands of nonconjugated nitro ($1556\text{--}1565$, $1364\text{--}1366\text{ cm}^{-1}$), sulfonyl ($1320\text{--}1329$, $1120\text{--}1126\text{ cm}^{-1}$) and NH ($3262\text{--}3274\text{ cm}^{-1}$) groups. ^1H NMR spectra of compounds **2a–d** fully correlate with their structures. For example, the spectrum of compound **2a** contains a singlet of methyl protons at 1.30 ppm. Methylene protons C^5H and nitromethine proton C^6H manifest an ABX spin system as a double doublets at 3.89 and 3.96 ppm ($^2J_{\text{H}^5\text{H}^6}$ 14.7 Hz, $^3J_{\text{H}^5\text{C}^6}$ 6.7 Hz, $^3J_{\text{H}^6\text{C}^6}$ 6.1 Hz) and a multiplet at 5.75 ppm. Methine protons at C^{3a} and C^3 and a proton at the nitrogen atom form an AMX system at 4.54 (d), 5.09 (dd), 5.53 (d) ppm ($^3J_{\text{HC}^3\text{C}^{3a}}$ 4.9 Hz, $^3J_{\text{HC}^3\text{NH}}$ 14.0 Hz). The low field contains signals of benzene rings (6.99–7.47 ppm).

X-ray diffraction of single crystal **2a**[§] reveals its monoclinic $P2_1/c$ space group. Pyrazolidine and sulfolane rings are *cis*-oriented, which supports the stereo efficient orientation of the substituents at bond $\text{C}(3a)\text{--}\text{C}(6a)$ (frozen conformation). Each cycle has an envelope conformation. Atom $\text{C}(3a)$ is out of the plane by 0.6 Å in the pyrazolidine cycle, atom $\text{C}(6a)$ in the sulfolane cycle, atom $\text{C}(6a)$ is out of the plane by 0.5 Å. The nitro group is *trans*-oriented towards the pyrazolidine cycle [torsion angle $\text{N}(1)\text{C}(6a)\text{C}(6)\text{N}(21)$, $170.4(1)^\circ$]. The angles between an average plane of the sulfolane




Figure 1 X-ray crystal structure of **2a**.

cycle and bonds $\text{S}=\text{O}(19)$ and $\text{S}=\text{O}(20)$ are $29.3(1)^\circ$ and $33.6(1)^\circ$, respectively. The bicyclic structure is also dependent on an intramolecular hydrogen bond between atom $\text{O}(20)$ of the sulfonyl group and the hydrogen atom at atom $\text{N}(2)$ [$\text{S}=\text{O}(20)\cdots\text{H}-\text{N}(2)$, 3.041 Å]. Chiral centers in molecule **2a**, $\text{C}(3)$, $\text{C}(3a)$, $\text{C}(6a)$, $\text{C}(6)$, have configurations *S*, *R*, *R*, *S*, respectively.

Thus, we have developed a convenient procedure for preparing new condensed bicyclic structures containing pyrazolidine and sulfolane rings from nitrothiolenes 1,1-dioxides and phenylhydrazine. The new compounds have potential in medicinal chemistry.

The work was supported by the Russian Ministry of Education and Science as a part of the base portion of the state task. X-ray diffraction analysis was carried out at the resource center 'X-ray diffraction studies', St. Petersburg State University.

$^3J_{\text{HC}^3\text{C}^{3a}}$ 4.9 Hz, $^3J_{\text{HC}^3\text{NH}}$ 14.0 Hz), 5.52 (d, 1H, NH, $^3J_{\text{HC}^3\text{NH}}$ 14.0 Hz), 5.75 (dd, 1H, C^6H , $^3J_{\text{H}^5\text{C}^6}$ 6.7 Hz, $^3J_{\text{H}^6\text{C}^6}$ 6.1 Hz), 6.99–7.03 (m, 1H, Ph), 7.26–7.29 (m, 4H, Ph), 7.21 (d, 2H, C_6H_4 , $^3J_{\text{HH}}$ 8.2 Hz), 7.34 (d, 2H, C_6H_4 , $^3J_{\text{HH}}$ 8.2 Hz). ^{13}C NMR, δ : 19.35 (Me), 20.58 (MeAr), 54.80 (C^5), 62.19 (C^3), 74.92 (C^{3a}), 77.38 (C^{6a}), 89.25 (C^6), 120.88, 123.07, 124.43, 128.79, 129.12, 131.29, 137.51, 147.29 (Ph, C_6H_4). Found (%): N, 11.16. Calc. for $\text{C}_{19}\text{H}_{21}\text{N}_3\text{O}_4\text{S}$ (%): N, 10.84.

[‡] Physico-chemical studies were performed at the Center for Collective Use of A. I. Herzen State Pedagogical University of Russia. ^1H , $^{13}\text{C}\{^1\text{H}\}$ NMR, $^1\text{H}\text{--}^{13}\text{C}$ HMQC, and $^1\text{H}\text{--}^{13}\text{C}$ HMBC spectra were recorded with a Jeol JNM ECX400A spectrometer operating at 399.78 (^1H) and 100.53 MHz (^{13}C) in CD_3CN solution; the signals of the residual nondeuterated solvents were used as internal standard. IR spectra were recorded with a Shimadzu IR-Prestige-21 Fourier spectrometer in KBr. Elemental analysis was performed with an Eurovector EA 3000 (CHN Dual mode) analyzer.

[§] For single crystal X-ray diffraction experiment, crystal of **2a** was fixed on a micro mount placed on an Agilent Technologies SuperNova Atlas diffractometer and measured at 100 K using microfocused monochromated $\text{CuK}\alpha$ radiation. The unit cell parameters (monoclinic, space group $P2_1/c$, $a = 12.2376(3)$, $b = 11.5358(2)$ and $c = 13.4551(3)\text{ Å}$, $\beta = 117.030(3)^\circ$, $V = 1691.99(8)\text{ Å}^3$, $Z = 4$) were refined by least square techniques using 14520 reflections in the 2θ range of $8.11\text{--}144.98^\circ$. The structure was solved by the direct methods and refined $R_1 = 0.040$ ($wR_2 = 0.101$) for 2996 unique reflections with $|F_0| \geq 4\sigma_F$ by means of the SHELXL-97 program¹⁰ incorporated in the OLEX2 program package.¹¹ The carbon and nitrogen-bound H atoms were placed in calculated positions and were included in the refinement in the 'riding' model approximation, with $U_{\text{iso}}(\text{H})$ set to $1.5U_{\text{eq}}(\text{C})$ and $\text{C}\text{--}\text{H}$ 0.96 Å for Me groups, $U_{\text{iso}}(\text{H})$ set to $1.2U_{\text{eq}}(\text{C})$ and $\text{C}\text{--}\text{H}$ 0.97 Å for CH_2 groups, $U_{\text{iso}}(\text{H})$ set to $1.2U_{\text{eq}}(\text{C})$ and $\text{C}\text{--}\text{H}$ 0.93 Å for CH groups, $U_{\text{iso}}(\text{H})$ set to $1.2U_{\text{eq}}(\text{C})$ and $\text{C}\text{--}\text{H}$ 0.98 Å for tertiary CH groups and $U_{\text{iso}}(\text{H})$ set to $1.2U_{\text{eq}}(\text{N})$ and $\text{N}\text{--}\text{H}$ 0.86 Å for NH groups. Empirical absorption correction was applied in CrysAlisPro¹² program complex using spherical harmonics implemented in SCALE3 ABSPACK scaling algorithm.

CCDC 1011950 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via <http://www.ccdc.cam.ac.uk>.

References

- M. G. Brant and J. E. Wulff, *Org. Lett.*, 2012, **14**, 5876.
- A. A. Eid, A. Koubeissi, R. Bou-Mjahed, N. Al Khalil, M. Farah, R. Maalouf, N. Nasser and K. H. Bouhadir, *Bioorg. Med. Chem. Lett.*, 2013, **23**, 174.
- A. Kiriazis, G. B. af Gennas, V. Talman, E. Ekokoski, T. Ruotsalainen, I. Kylanlahti, T. Ruffer, G. Wissel, H. Xhaard, H. Lang, R. K. Tuominen and J. Yli-Kauhaluoma, *Tetrahedron*, 2011, **67**, 8665.
- B. Li, R. A. Buzon and B. Hritzko, *Synlett.*, 2012, **23**, 131.
- S. S. Y. Wong, M. G. Brant, C. Barr, A. G. Oliver and J. E. Wulff, *Beilstein J. Org. Chem.*, 2013, **9**, 1419.
- G. A. Tolstikov, E. E. Shul'ts, G. F. Vafina and L. V. Spirikhin, *Russ. J. Org. Chem.*, 1992, **28**, 157 (*Zh. Org. Khim.*, 1992, **28**, 192).
- G. A. Tolstikov, E. E. Shul'ts, G. F. Vafina, L. V. Spirikhin and A. A. Panasenkov, *J. Org. Chem. USSR (Engl. Transl.)*, 1989, **25**, 1109 (*Zh. Org. Khim.*, 1989, **25**, 1231).
- V. M. Berestovitskaya, *Russ. J. Gen. Chem.*, 2000, **70**, 1419 (*Zh. Obshch. Khim.*, 2000, **70**, 1512).
- V. M. Berestovitskaya, M. V. Selivanova, M. I. Vakulenko, I. E. Efremova and G. A. Berkova, *Russ. J. Org. Chem.*, 2009, **45**, 1814 (*Zh. Org. Khim.*, 2009, **45**, 1818).
- G. M. Sheldrick, *Acta Crystallogr., Sect. A*, 2008, **64**, 112.
- O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard and H. Puschmann, *J. Appl. Crystallogr.*, 2009, **42**, 339.
- CrysAlisPro, Version 1.171.36.32*, Agilent Technologies, 2013.

Received: 10th October 2014; Com. 14/4481